GNPX
MaterialsGenprex Inc
$0.89+0.01 (+0.58%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving GNPX Today?
No stock-specific AI insight has been generated for GNPX yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$9M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume386K
Avg Volume (10D)—
Shares Outstanding10.4M
GNPX News
20 articles- Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat CancerYahoo Finance·Apr 30, 2026
- Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual MeetingYahoo Finance·Apr 28, 2026
- Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual MeetingYahoo Finance·Apr 22, 2026
- Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene TherapyYahoo Finance·Apr 21, 2026
- Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual MeetingYahoo Finance·Apr 20, 2026
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual MeetingYahoo Finance·Mar 18, 2026
- Genprex to Participate at BIO Europe Spring 2026Yahoo Finance·Mar 10, 2026
- Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat CancerYahoo Finance·Feb 23, 2026
- Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat CancersYahoo Finance·Feb 10, 2026
- Genprex Provides Clinical Update on Diabetes Gene Therapy ProgramYahoo Finance·Jan 7, 2026
- Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal StudiesYahoo Finance·Jan 6, 2026
- Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung CancerYahoo Finance·Nov 24, 2025
- Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical TrialsYahoo Finance·Nov 19, 2025
- Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat CancersYahoo Finance·Nov 18, 2025
- Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat CancerYahoo Finance·Nov 4, 2025
- Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq RulesYahoo Finance·Oct 28, 2025
- Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsYahoo Finance·Oct 28, 2025
- Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq RulesYahoo Finance·Oct 23, 2025
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer TherapeuticsYahoo Finance·Oct 23, 2025
- Q3 Virtual Investor Summit: On-Demand Presentations Now AvailableYahoo Finance·Sep 30, 2025
All 20 articles loaded
Price Data
Open$0.88
Previous Close$0.89
Day High$0.91
Day Low$0.88
52 Week High—
52 Week Low—
Fundamentals
Market Cap$9M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume386K
Avg Volume (10D)—
Shares Outstanding10.4M
About Genprex Inc
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—